Bicara Therapeutics Inc. (BCAX) Income Statement
BCAX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBCAX revenue and net income
BCAX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BCAX quarterly EPS vs estimates
Bicara Therapeutics beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.84).
BCAX income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $56,000 | $19,000 | $10,000 |
| Gross profit | — | −$56,000 | −$19,000 | −$10,000 |
| Research & development | $125.1M | $63.6M | $30.6M | $31.3M |
| Sales, general & admin | $30.5M | $18.8M | $9.3M | $6.3M |
| Total operating expenses | $155.6M | $82.4M | $39.9M | $37.7M |
| Operating income | −$155.6M | −$82.4M | −$39.9M | −$37.7M |
| Interest income | $17.9M | $14.6M | $1.3M | $4,000 |
| Interest expense | — | — | $0 | $112,000 |
| Income before taxes | −$137.7M | −$67.8M | −$52.0M | −$37.8M |
| Income taxes | $217,000 | $187,000 | $5,000 | $1,000 |
| Net income | −$137.9M | −$68.0M | −$52.0M | −$37.8M |
| EBITDA | −$137.6M | −$67.8M | −$52.0M | −$37.7M |
| EPS (diluted) | −$2.53 | −$2.44 | −$0.98 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | $19,000 | $19,000 | $15,000 | $15,000 | $13,000 | $13,000 | — | $2,000 |
| Gross profit | — | — | — | — | −$19,000 | −$19,000 | −$15,000 | −$15,000 | −$13,000 | −$13,000 | — | −$2,000 |
| Research & development | $45.8M | $47.5M | $33.0M | $5.8M | $24.8M | $34.3M | $19.9M | $15.9M | $15.8M | $12.0M | $10.6M | $6.9M |
| Sales, general & admin | $14.2M | $12.7M | $8.1M | $7.7M | $7.2M | $7.5M | $6.8M | $4.8M | $3.9M | $3.3M | $3.1M | $2.6M |
| Total operating expenses | $60.0M | $60.2M | $41.1M | $40.7M | $32.0M | $41.8M | $26.6M | $20.6M | $19.8M | $15.4M | $13.7M | $9.5M |
| Operating income | −$60.0M | −$60.2M | −$41.1M | −$40.7M | −$32.0M | −$41.8M | −$26.6M | −$20.6M | −$19.8M | −$15.4M | −$13.7M | −$9.5M |
| Interest income | $4.6M | $4.1M | $3.8M | $4.4M | $4.7M | $5.0M | $5.9M | $3.1M | $2.7M | $2.9M | $1.3M | $13,000 |
| Income before taxes | −$55.4M | −$56.2M | −$37.3M | −$36.3M | −$27.3M | −$36.8M | −$20.8M | −$17.5M | −$17.0M | −$12.5M | −$12.4M | −$22.8M |
| Income taxes | $61,000 | −$52,000 | $53,000 | $40,000 | $52,000 | $72,000 | $186,000 | — | $500 | $1,000 | $5,000 | — |
| Net income | −$55.4M | −$56.2M | −$37.4M | −$36.3M | −$27.4M | −$36.8M | −$21.0M | −$17.5M | −$17.0M | −$12.5M | −$12.4M | −$22.8M |
| EBITDA | −$55.3M | −$56.1M | −$37.3M | −$36.3M | −$27.3M | −$36.8M | −$20.8M | −$17.5M | −$17.0M | −$12.5M | −$25.8M | −$22.8M |
| EPS (diluted) | −$0.82 | −$0.93 | −$0.68 | −$0.67 | −$0.50 | −$0.68 | −$0.39 | −$1.60 | −$0.45 | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BCAX's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BCAX financial results
Bicara Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $137.9 million. Diluted earnings per share came to −$2.53.
See the BCAX stock overview for the latest quote and news, or the BCAX chart for price history and technical indicators.
BCAX income statement FAQ
Does Bicara Therapeutics have revenue?
Bicara Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Bicara Therapeutics profitable?
No. Bicara Therapeutics reported a net loss of $137.9 million in fiscal 2025.
How much does Bicara Therapeutics spend on research and development?
Bicara Therapeutics spent $125.1 million on research and development in fiscal 2025.
What are Bicara Therapeutics's earnings per share?
Bicara Therapeutics earned $-2.53 per diluted share in fiscal 2025, compared with $-2.44 a year earlier.
When will Bicara Therapeutics report its next earnings?
Bicara Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Bicara Therapeutics's fiscal year end?
Bicara Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.